Stock comparison
Artivion
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AORT
Artivion
Market cap
$1.09B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AORT | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 35D | 77B | LMAT |
| Benjamin Graham | 63D | 89A | LMAT |
| Philip Fisher | 48D | 81C | LMAT |
| Peter Lynch | 32F | 67B | LMAT |
| Joel Greenblatt | 41D | 56D | LMAT |
| Charlie Munger | 43D | 68D | LMAT |
| Terry Smith | 36D | 69D | LMAT |
Side-by-side metrics
| Metric | AORT | LMAT |
|---|---|---|
| Market cap | $1.09B | $2.23B |
| P/E (TTM) | 93.6x | 37.1x |
| EV/EBIT | 48.9x | 36.6x |
| ROIC (TTM) | 3.0% | 9.43% |
| Gross margin | 62.94% | 72.39% |
| Net margin | 2.55% | 24.35% |
| Revenue CAGR 5y | 10.24% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 0.6x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AORT leads on
No clear edges - the other side wins or ties on every measured metric.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 2.55%+90%
- ROIC (TTM)9.43%vs 3.0%+68%
- P/E (TTM)37.1xvs 93.6x+60%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.